
U.S. Stocks Decline, Paring Weekly Gain; Shares of Amgen Drop
Sept. 19 (Bloomberg) -- U.S. stocks declined, paring their biggest weekly gain in more than three months, on concern the pace of earnings growth will fail to support share prices.
``The market may have come a little too far, too soon,'' said Forrest Mervine, who helps manage more than $1.3 billion at Philadelphia Corp. in Philadelphia. ``The enthusiasm for a recovery in the market has perhaps gotten ahead of itself.''
Amgen Inc., the world's largest biotechnology company, declined after Wachovia Securities said earnings growth may disappoint some investors. AmerisourceBergen Corp. fell after the Wall Street Journal reported that regulators and the Federal Bureau of Investigation are investigating the biggest U.S. drug wholesaler over rebates from drugmakers.
The Standard & Poor's 500 Index lost 3.28, or 0.3 percent, to 1036.30, with health-care companies accounting for almost half of the drop. The Dow Jones Industrial Average fell 14.31, or 0.2 percent, to 9644.82. The Nasdaq Composite Index shed 3.85, or 0.2 percent, to 1905.70.
Companies in the S&P 500 trade at 19 times earnings forecast for this year, the highest ratio since June 2002 and up from 15 times when the index touched its 2003 low in March, according to Thomson Financial.
Stocks climbed this week as encouraging economic reports and the Federal Reserve's decision to keep interest rates at the lowest in 45 years boosted confidence that profits will increase.
The S&P 500 added 1.7 percent this week and the Dow average rose 1.8 percent, their biggest gains since the period ended June 6. The Nasdaq jumped 2.7 percent, its best week in five.
2003 Gains
Even with today's decline, the S&P 500 is up 18 percent in 2003. The Nasdaq has surged 43 percent and the Dow has added 16 percent.
``We could have another leg to this rally,'' said Benjamin Pace, who helps oversee $22 billion at Deutsche Private Wealth Management, in a radio interview with Bloomberg News. ``We're looking for companies to beat'' earnings expectations, he said.
Analysts predict on average that corporate profits will rise 15 percent this quarter and 22 percent next, according to a Thomson Financial poll. Higher-than-expected earnings in the first half of 2003 helped fuel the rally in stocks this year.
Six stocks rose for every five that fell on the New York Stock Exchange today. Some 1.46 billion shares changed hands on the Big Board, 9.6 percent more than the three-month daily average.
Amgen Falls
Amgen lost $1.11 to $68.89. The company will be unable to meet investor expectations of 20 percent annual earnings growth over the next five years because of increased competition in anemia medicines, said Wachovia Securities Inc. analyst Martin Auster in Baltimore. He cut the stock's rating to ``market perform'' from ``outperform.''
AmerisourceBergen fell $1.82 to $54.83. The Wall Street Journal reported that the Food and Drug Administration and the FBI are probing whether the company profited by diverting drugs into a secondary market and receiving rebates more than once on a single sale.
The case doesn't involve AmerisourceBergen's purchase of products from the gray market, spokesman Michael Kilpatric told the paper. The company in a statement denied the allegations.
Newell Rubbermaid Inc., the maker of Calphalon cookware, fell $1.57 to $22.43 for the biggest decline in the S&P 500. The stock slid as much as 10 percent after the company canceled a meeting with analysts. Newell didn't return a call for comment.
Expeditors Drops
Expeditors International of Washington Inc. slid $2.84 to $36.15. The manager of freight shipments expects third-quarter profit of 28 cents to 30 cents a share, less than an average estimate of 33 cents in a Thomson Financial poll. Expeditors' Asian air-freight unit made less money last month and the company doesn't expect business to improve this month.
Viacom Inc. fell $1.54 to $42.06. The owner of the CBS television network has had less-than-expected local political advertising at its TV stations, said Merrill Lynch & Co. analyst Jessica Reif Cohen. She lowered revenue estimates for the third quarter and reiterated her ``buy'' rating on the stock.
Nike Inc., world's largest maker of athletic shoes, surged $4.25 to $61.50 for the biggest gain in the S&P 500. The company reported fiscal first-quarter net income of 98 cents a share, 10 cents more than the estimate in a Thomson Financial poll. U.S. orders for sneakers with the Nike ``swoosh'' increased last quarter for the first time in more than a year.
Reebok International Ltd., Nike's smaller rival, added $1.72 to $34.34.
Tyco International Ltd., the world's biggest maker of security systems and industrial valves, rose 90 cents to $21.90. J.P. Morgan analyst Don MacDougall said Tyco shares are undervalued. He expects the stock to climb to $30 in the next 12 months and added it to the firm's ``Focus List.''
Licensing Pact
Protein Design Labs Inc., which develops treatments based on immune-system proteins called antibodies, jumped 59 cents to $14.71. The company extended a licensing agreement with Genentech Inc., the world's second-biggest biotechnology company, for five years. Under the existing deal, the companies can exercise options to use each other's technology or license patent rights. Genentech added $1.37 to $87.72.
Cell Therapeutics Inc. advanced 80 cents to $12.10. The biotechnology company may announce positive results from clinical trials of the chemotherapy drug Xyotax, helping its stock reach $30 in a year, Business Week reported in its ``Inside Wall Street'' column, citing Edward Hemmelgarn, president of Shaker Investments Inc., which owns the stock.
Futures
S&P 500 futures expiring in December lost 4.40 to 1032.90 on the Chicago Mercantile Exchange. Nasdaq-100 Index futures shed 6.50 to 1394.50. The index, a benchmark for Nasdaq's largest companies, decreased 7.87 to 1392.26.
Nasdaq-100 tracking shares, known by their QQQ ticker symbol, fell 20 cents to $34.58. The S&P 500 shares, called Spiders, dropped 93 cents to $103.67.
The Russell 2000 Index of small stocks added 0.74, or 0.1 percent, to 520.20.
AmerisourceBergen Corp. (ABC)
Amgen Inc. (AMGN)
Cell Therapeutics Inc. (CTIC)
Genentech Inc. (DNA)
Expeditors International of Washington Inc. (EXPD)
Newell Rubbermaid Inc.
Nike Inc. (NKE)
Protein Design Labs Inc. (PDLI)
Reebok International Ltd. (RBK)
Tyco International Ltd. (TYC)
Viacom Inc. (VIA)
Last Updated: September 19, 2003 17:20 EDT
Sept. 19 (Bloomberg) -- U.S. stocks declined, paring their biggest weekly gain in more than three months, on concern the pace of earnings growth will fail to support share prices.
``The market may have come a little too far, too soon,'' said Forrest Mervine, who helps manage more than $1.3 billion at Philadelphia Corp. in Philadelphia. ``The enthusiasm for a recovery in the market has perhaps gotten ahead of itself.''
Amgen Inc., the world's largest biotechnology company, declined after Wachovia Securities said earnings growth may disappoint some investors. AmerisourceBergen Corp. fell after the Wall Street Journal reported that regulators and the Federal Bureau of Investigation are investigating the biggest U.S. drug wholesaler over rebates from drugmakers.
The Standard & Poor's 500 Index lost 3.28, or 0.3 percent, to 1036.30, with health-care companies accounting for almost half of the drop. The Dow Jones Industrial Average fell 14.31, or 0.2 percent, to 9644.82. The Nasdaq Composite Index shed 3.85, or 0.2 percent, to 1905.70.
Companies in the S&P 500 trade at 19 times earnings forecast for this year, the highest ratio since June 2002 and up from 15 times when the index touched its 2003 low in March, according to Thomson Financial.
Stocks climbed this week as encouraging economic reports and the Federal Reserve's decision to keep interest rates at the lowest in 45 years boosted confidence that profits will increase.
The S&P 500 added 1.7 percent this week and the Dow average rose 1.8 percent, their biggest gains since the period ended June 6. The Nasdaq jumped 2.7 percent, its best week in five.
2003 Gains
Even with today's decline, the S&P 500 is up 18 percent in 2003. The Nasdaq has surged 43 percent and the Dow has added 16 percent.
``We could have another leg to this rally,'' said Benjamin Pace, who helps oversee $22 billion at Deutsche Private Wealth Management, in a radio interview with Bloomberg News. ``We're looking for companies to beat'' earnings expectations, he said.
Analysts predict on average that corporate profits will rise 15 percent this quarter and 22 percent next, according to a Thomson Financial poll. Higher-than-expected earnings in the first half of 2003 helped fuel the rally in stocks this year.
Six stocks rose for every five that fell on the New York Stock Exchange today. Some 1.46 billion shares changed hands on the Big Board, 9.6 percent more than the three-month daily average.
Amgen Falls
Amgen lost $1.11 to $68.89. The company will be unable to meet investor expectations of 20 percent annual earnings growth over the next five years because of increased competition in anemia medicines, said Wachovia Securities Inc. analyst Martin Auster in Baltimore. He cut the stock's rating to ``market perform'' from ``outperform.''
AmerisourceBergen fell $1.82 to $54.83. The Wall Street Journal reported that the Food and Drug Administration and the FBI are probing whether the company profited by diverting drugs into a secondary market and receiving rebates more than once on a single sale.
The case doesn't involve AmerisourceBergen's purchase of products from the gray market, spokesman Michael Kilpatric told the paper. The company in a statement denied the allegations.
Newell Rubbermaid Inc., the maker of Calphalon cookware, fell $1.57 to $22.43 for the biggest decline in the S&P 500. The stock slid as much as 10 percent after the company canceled a meeting with analysts. Newell didn't return a call for comment.
Expeditors Drops
Expeditors International of Washington Inc. slid $2.84 to $36.15. The manager of freight shipments expects third-quarter profit of 28 cents to 30 cents a share, less than an average estimate of 33 cents in a Thomson Financial poll. Expeditors' Asian air-freight unit made less money last month and the company doesn't expect business to improve this month.
Viacom Inc. fell $1.54 to $42.06. The owner of the CBS television network has had less-than-expected local political advertising at its TV stations, said Merrill Lynch & Co. analyst Jessica Reif Cohen. She lowered revenue estimates for the third quarter and reiterated her ``buy'' rating on the stock.
Nike Inc., world's largest maker of athletic shoes, surged $4.25 to $61.50 for the biggest gain in the S&P 500. The company reported fiscal first-quarter net income of 98 cents a share, 10 cents more than the estimate in a Thomson Financial poll. U.S. orders for sneakers with the Nike ``swoosh'' increased last quarter for the first time in more than a year.
Reebok International Ltd., Nike's smaller rival, added $1.72 to $34.34.
Tyco International Ltd., the world's biggest maker of security systems and industrial valves, rose 90 cents to $21.90. J.P. Morgan analyst Don MacDougall said Tyco shares are undervalued. He expects the stock to climb to $30 in the next 12 months and added it to the firm's ``Focus List.''
Licensing Pact
Protein Design Labs Inc., which develops treatments based on immune-system proteins called antibodies, jumped 59 cents to $14.71. The company extended a licensing agreement with Genentech Inc., the world's second-biggest biotechnology company, for five years. Under the existing deal, the companies can exercise options to use each other's technology or license patent rights. Genentech added $1.37 to $87.72.
Cell Therapeutics Inc. advanced 80 cents to $12.10. The biotechnology company may announce positive results from clinical trials of the chemotherapy drug Xyotax, helping its stock reach $30 in a year, Business Week reported in its ``Inside Wall Street'' column, citing Edward Hemmelgarn, president of Shaker Investments Inc., which owns the stock.
Futures
S&P 500 futures expiring in December lost 4.40 to 1032.90 on the Chicago Mercantile Exchange. Nasdaq-100 Index futures shed 6.50 to 1394.50. The index, a benchmark for Nasdaq's largest companies, decreased 7.87 to 1392.26.
Nasdaq-100 tracking shares, known by their QQQ ticker symbol, fell 20 cents to $34.58. The S&P 500 shares, called Spiders, dropped 93 cents to $103.67.
The Russell 2000 Index of small stocks added 0.74, or 0.1 percent, to 520.20.
AmerisourceBergen Corp. (ABC)
Amgen Inc. (AMGN)
Cell Therapeutics Inc. (CTIC)
Genentech Inc. (DNA)
Expeditors International of Washington Inc. (EXPD)
Newell Rubbermaid Inc.
Nike Inc. (NKE)
Protein Design Labs Inc. (PDLI)
Reebok International Ltd. (RBK)
Tyco International Ltd. (TYC)
Viacom Inc. (VIA)
Last Updated: September 19, 2003 17:20 EDT